[HTML] sciencedirect.com

[HTML][HTML] Improving safety and outcomes after allogeneic hematopoietic cell transplantation: a single-center experience

MQ Salas, I Pasic, M Remberger… - … and Cellular Therapy, 2022 - Elsevier
The implementation of dual T-cell depletion comprising 4.5 mg/kg of antithymocyte globulin
(ATG), post-transplantation cyclophosphamide, and cyclosporine A for reduced-intensity …
被引用次数：9 相关文章

Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience

MQ Salas, I Pasic, M Remberger… - … and Cellular Therapy, 2022 - diva-portal.org
The implementation of dual T-cell depletion comprising 4.5 mg/kg of antithymocyte globulin
(ATG), post-transplantation cyclophosphamide, and cyclosporine A for reduced-intensity …
[HTML] astctjournal.org

[HTML][HTML] Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience

MQ Salas, I Pasic, M Remberger… - … and Cellular Therapy …, 2022 - astctjournal.org
The implementation of dual T-cell depletion comprising 4.5 mg/kg of antithymocyte globulin
(ATG), post-transplantation cyclophosphamide, and cyclosporine A for reduced-intensity …

Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience

MQ Salas, I Pasic, M Remberger… - Transplantation …, 2022 - pubmed.ncbi.nlm.nih.gov
The implementation of dual T-cell depletion comprising 4.5 mg/kg of antithymocyte globulin
(ATG), post-transplantation cyclophosphamide, and cyclosporine A for reduced-intensity …

Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience.

MQ Salas, I Pasic, M Remberger… - … and Cellular Therapy, 2022 - europepmc.org
The implementation of dual T-cell depletion comprising 4.5 mg/kg of antithymocyte globulin
(ATG), post-transplantation cyclophosphamide, and cyclosporine A for reduced-intensity …